Neurogene downgraded to Neutral at Baird on regulatory uncertainty
Source: SeekingAlpha
2025-05-16 11:18:39 ET
More on Neoleukin Therapeutics
- Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
- Neurogene GAAP EPS of -$1.08 misses by $0.02
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Seeking Alpha’s Quant Rating on Neoleukin Therapeutics
- Historical earnings data for Neoleukin Therapeutics
Read the full article on Seeking Alpha
For further details see:
Neurogene downgraded to Neutral at Baird on regulatory uncertainty
Neurogene Inc.
NASDAQ: NGNE
NGNE Trading
-2.63% G/L:
$26.29 Last:
32,731 Volume:
$26.52 Open:
NGNE Latest News
April 28, 2026 07:30:00 am
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 20, 2026 07:30:00 am
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 04, 2026 06:40:44 am
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
March 24, 2026 07:30:00 am
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
NGNE Stock Data
$263,326,600
13,686,787
0.57%
9
N/A
Pharmaceuticals
Healthcare
US
New York
